We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRDA:LSECroda International Plc Analysis

Data as of 2026-03-11 - not real-time

£2,742.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Croda International (CRDA.L) is trading at £2,742, well below its 20‑day SMA of £2,959 and its 50‑day SMA of £2,855, indicating a short‑term price weakness that aligns with a bearish MACD histogram of –£43.2 and a RSI of 39.5, suggesting the stock may be oversold. Despite the oversold signal, the company’s forward earnings per share of £1.77 versus a trailing EPS of £0.44 points to a strong earnings rebound, reflected in a forward P/E of 15.5 compared with a trailing P/E of 62.3. The dividend yield remains attractive at 3.99%, but a payout ratio of 250% raises questions about sustainability. Recent news highlights a potential margin expansion as sales climb, and JPMorgan’s reaffirmation of an ‘overweight’ rating has spurred a 7.6% rally, adding momentum to the upside. The DCF fair‑value estimate of £1,081 is far below the current price, reinforcing the view that the market may be overvaluing the stock relative to fundamentals. Volatility is elevated at 46% over the past 30 days, while beta is low (≈0.16), suggesting limited systematic risk but high idiosyncratic price swings. The support level at £2,626 and resistance at £3,312 frame a modest upside potential of roughly 28% if the stock can reclaim higher moving averages.
Given the high valuation multiples (PE 62x, PB 175x) and an unsustainable dividend payout, investors should be cautious about long‑term price appreciation. The sector’s exposure to regulatory scrutiny and global economic cycles adds medium‑level sector and regulatory risk. However, the company’s diversified geographic footprint and solid cash generation (operating cash flow £286.5 m) mitigate some of the geographic and liquidity concerns. Overall, the technical oversold conditions combined with fundamental earnings growth create a short‑term buying opportunity, but the elevated valuation tempers confidence for a prolonged hold.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI indicating potential bounce
  • Support level at £2,626 providing a floor
  • Recent positive analyst sentiment and price rally

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward earnings growth (EPS forecast £1.77)
  • Margin expansion expectations from higher sales
  • Attractive dividend yield despite payout concerns

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High valuation multiples (PE 62x, PB 175x)
  • Unsustainable dividend payout ratio
  • Sector cyclicality and regulatory exposure

Key Metrics & Analysis

Financial Health

Revenue Growth3.90%
Profit Margin3.65%
P/E Ratio62.3
ROE2.88%
ROA4.80%
Debt/Equity31.63
P/B Ratio175.0
Op. Cash Flow£286.5M
Free Cash Flow£123.6M

Technical Analysis

TrendBullish
RSI39.5
Support£2,626.00
Resistance£3,312.00
MA 20£2,958.90
MA 50£2,855.20
MA 200£2,796.27
MACDBearish
VolumeDecreasing
Fear & Greed Index77.98

Valuation

Fair Value£1,081.26
Target Price£3,531.43
Upside/Downside28.79%
GradeOvervalued
TypeBlend
Dividend Yield3.99%

Risk Assessment

Beta0.16
Volatility46.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.